Skip to main content

Exact Sciences Value Stock - Dividend - Research Selection

Exact sciences

ISIN: US30063P1057 , WKN: 590273

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Uranium ETF shines while ARK Genomic Revolution ETF struggles

2023-09-22
In a striking contrast of fortunes in the Exchange-Traded Fund (ETF) market on Friday, the Uranium ETF outperformed its peers, while the ARK Genomic Revolution ETF struggled.

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year

2023-09-21
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Notable Two Hundred Day Moving Average Cross - EXAS

2023-09-20
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), Alnylam Pharma (ALNY) and GoodRx Holdings (GDRX)

2023-09-14
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience

2023-09-12
SANTA CLARA, Calif. & MADISON, Wis., September 12, 2023--Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party.

Agilent, Exact Sciences agree to terms on Resolution Bioscience

2023-09-12
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Where Will Exact Sciences Be in 5 Years?

2023-09-09
Over the past five years, Exact Sciences (NASDAQ: EXAS) hasn't delivered great returns. Exact Sciences develops cancer diagnostic tests. It is best known for its at-home, noninvasive colorectal cancer screening option, Cologuard.

Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs

2023-09-07
Exact Sciences (EXAS) is improving customer experience by making it simpler to order Cologuard electronically and continue re-screening of patients every three years.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

2023-09-07
Investors are optimistic about Exact Sciences (EXAS), backed by Cologuard growth and upbeat guidance.

The 3 Best Cathie Wood Stocks to Buy Now: September 2023

2023-09-06
I disagree with Cathie Wood’s stock picks much if not most of the time. For example, I believe that her huge bullishness on Bitcoin (BTC-USD) is completely misplaced, given the clear opposition of the U.S. government and most large American banks to cryptos. And I also think that her optimism about Tesla (NASDAQ:TSLA) is overdone in light of the stock’s high valuation and tough competition. Finally, I believe that Wood’s embrace of the metaverse is unwarranted since the technology has been aroun